Glycogen storage diseases (GSDs) constitute a group of inherited metabolic disorders that impair normal glycogen synthesis or degradation, resulting in the accumulation of structurally abnormal ...

Researchers from Maze Therapeutics Inc. presented the discovery and preclinical characterization of a novel selective small-molecule inhibitor of glycogen synthase 1 (GYS1), MZ-101, as a potential ...